Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Sedana Medical's CEO Christer Ahlberg is leaving the company

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Christer Ahlberg has informed the board of directors of Sedana Medical that he is resigning as CEO to become CEO of Cinclus Pharma AB. Christer Ahlberg will remain as CEO until the…

First patient included in pediatric study IsoCOMFORT

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient has been included in the company's pediatric study IsoCOMFORT (SED002) which is conducted to investigate if inhaled sedation of Sedaconda (isoflurane) via AnaConDa…

Sedana Medical submits application for market approval in UK

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane) for inhaled sedation in intensive care in the UK.

Sedana Medical presents research grant recipients 2020

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the recipients of the Sedana Medical Research Grant 2020. The grant is a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pat…

Sedana Medical’s Sedaconda study presented at ESICM

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that outcomes from some of the secondary endpoints of the company’s pivotal study, Sedaconda (SED-001, formerly known as the IsoConDa-study) were presented at the leading congress ESICM…

Sedana Medical receives additional patent for AnaConDa

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has been granted another patent regarding the medical device AnaConDa. The technology that the patent protects enables a reduction of the so-called dead space with the h…

Sedana Medical’s nomination committee appointed

Regulatory

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 19, 2020, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…

AnaConDa from Sedana Medical reviewed by NICE in UK

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of AnaConDa as an alternative to intravenous sedation in…

Sedana Medical appoints new CFO

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Susanne Andersson has been appointed new CFO and will take office during the first quarter of 2021. Susanne Andersson succeeds Maria Engström, who on her own initiative has chosen t…

Sedana Medical: Exercise of warrants in incentive program 2017/21

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that all warrants in the company's incentive program 2017/21 have been exercised by the warrant holders, leading to an increase in the number of shares and votes in the company by 310,14…

Bulletin from the Annual General Meeting in Sedana Medical

Regulatory

Today, May 19, 2020, the annual general meeting of Sedana Medical AB (publ) (”Sedana Medical” or the "Company") was held in Stockholm. The general meeting resolved to adopt all of the board of directors’ and the nomination committee’s resolution prop…